Infusional Chemotherapy for Non-Hodgkin's Lymphoma

References

• Lai G M, Chen Y N, Mickley L A, et al. P-glycoprotein expression and schedule dependence of adriamycin cytotoxicity in human colon carcinoma cell lines. Intl J Cancer 1991; 49: 697–703
   Google Scholar
• Young R C, Schein P S. Enhanced antitumor effect of cytosine arabinoside given in a schedule dictated by kinetic studies in vivo. Biochem Pharmacol 1973; 22: 277–280
   PubMed Web of Science ®Google Scholar
• Lopes N M, Adams E G, Pilts T W, et al. Cell kill kinetics and cell cycle effects of taxol on human and hamster ovarian cell lines. Cancer Chemother Pharmacol 1993; 32: 235–242, Wilson, et al.
   PubMed Web of Science ®Google Scholar
• Sachs L, Lolem J. Control of programmed cell death in norml and leukemic cells: New implications for therapy. Blood 1993; 82: 15–21
   PubMed Web of Science ®Google Scholar
• Kohn K W, Jackman J, O'Connor P M. Cell cycle control and cancer chemotherapy. J Cell Biochem 1994; 54: 440–452
   PubMed Web of Science ®Google Scholar
• Prokocimer M, Rotter V. Structure and function of p53 in normal cells and their aberrations in cancer cells: Projection on the hematologic cell lineages. Blood 1994; 84: 2391–2411
   PubMed Web of Science ®Google Scholar
• Piris M A, Pezella F, Martinez-Montero J C, et al. p53 and bcl-2 expression in high-grade B-cell lymphomas: Correlation with survival time. Br J Cancer 1994; 69: 337–341
   PubMed Web of Science ®Google Scholar
• Wilson W H, Teruya-Feldstein J, Harris J, et al. p53 but not bcl-2 overexpression is independently associated with drug resistance in relapsed non-Hodgkin's lymphomas treated with EPOCH chemotherapy. Proc Am Soc Clin Oncol 1225; 14: 1225, (abstract)
   Google Scholar
• Harris C C, Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N Engl J Med 1993; 329: 1318–1327
   PubMed Web of Science ®Google Scholar
• Hryniuk W, Busch H. The importance of dose intensity in chemotherapy of Metastatic breast cancer. J Clin Oncol 1994; 2: 1281–1288
   Google Scholar
• Hryniuk W, Levine M N. Analysis of dose intensity for adjuvant chemotherapy trials in stage II breast cancer. J Clin Oncol 1986; 4: 1162–1170
   PubMed Web of Science ®Google Scholar
• Goldstein L, Galaski H, Fojo A, et al. Expression of a multidrug resistance gene in human cancers. J Natl Cancer Inst 1989; 81: 116–120
   PubMed Web of Science ®Google Scholar
• Miller T, Grogan T, Dallon W, et al. P-glycoprotein expression in malignant lymphoma and reversal of clinical drug resistance with chemotherapy plus high-dose verapamil. J Clin Oncol 1991; 9: 17–24
   PubMed Web of Science ®Google Scholar
• Wilson W H, Bates S E, Fojo A, et al. Controlled trial of dexvera-pamil, a modulator of multidrug resistance, in lymphomas refractory to EPOCH chemotherapy. J Clin Oncol 1995; 13: 1995–2004
   PubMed Web of Science ®Google Scholar
• Pastan I, Gottesmann M. Multiple-drug resistance in humancancer. N Engl J Med 1987; 316: 1388–1993
   PubMed Web of Science ®Google Scholar
• Chabner B A, Bases S E, Fojo A T, et al. Drug resistance in adult lymphomas. Semin Heme 1994; 31: 70–87
   PubMed Web of Science ®Google Scholar
• Umezawa H, Meada K, Takeuchi T, et al. New antibiotics: Bleomycin A and B. J Antibiot (Tokyo) 1966; 19: 200–206
   PubMed Web of Science ®Google Scholar
• Hall S W, Strong J E, Braughton A. Bleomycin clinical pharmacology by radioimmunoassay. Cancer Chemother Pharmacol 1982; 9: 22–25
   PubMed Web of Science ®Google Scholar
• Broughton A, Strong J E, Hobye P Y, et al. Clinical pharmacology of bleomycin following intravenous infusion as determined by radioimmunoassay. Cancer 1977; 40: 2772–2778
   PubMed Web of Science ®Google Scholar
• Parvinen L M, Kilkku P, Maekinen E, et al. Factors affecting the pulmonary toxicity of bleomycin. Acta Radiol 1983; 22: 417–422
   Web of Science ®Google Scholar
• Drewinko B, Novak J N, Barranco S C. The response of human lymphoma cells in vitro to bleomycin and 1, 3-bis(2chloroethyi)-1-nitrosourea. Cancer Res 1972; 32: 1206–1208
   PubMed Web of Science ®Google Scholar
• Ludwig R, Alberts D S, Miller T P, et al. Evaluation of anticancer drug schedule dependency using an in vitro human tumor clonogenic assay. Cancer Chemother Pharmacol 1984; 12: 135–142
   PubMed Web of Science ®Google Scholar
• Matsushima Y, Kanzawa F, Hoshi A, et al. Time schedule dependency of the inhibiting activity of various anticancer drugs in the clonogenic assay. Cancer Chemother Pharmacol 1985; 14: 104–107
   PubMed Web of Science ®Google Scholar
• Sikic B I, Collins J M, Mimnaugh E G, et al. Improved therapeutic index of bleomycin when administered by continuous infusion in mice. Cancer Treat Rep 1978; 62: 2011–2017
   PubMedGoogle Scholar
• Cooper K R, Hong W K. Prospective study of the pulmonary toxicity of continuously infused bleomycin. Cancer Treat Rep 1981; 65: 419–425
   PubMedGoogle Scholar
• Owellen R J, Hartke C A, Dickerson R M, et al. Inhibition of tubulin-microtubule polymerization by drugs of the vinca alkaloidclass. Cancer Res 1976; 36: 1499–1502
   PubMed Web of Science ®Google Scholar
• Culp W H, Daniels W D, McMahon R E. Disposition and tissue levels of [3H]vindesine in rats. Cancer Res 1977; 37: 3053–3056
   PubMed Web of Science ®Google Scholar
• Jackson D V, Paschold C H, Spur C L, et al. Treatment of advanced non-Hodgkin's lymphoma with vincristine infusion. Cancer 1984; 53: 2601–2606
   PubMed Web of Science ®Google Scholar
• Ghen G L, Yang L, Rowe T C, et al. Nonintercalative antitumor drugs interfere with the breakage-reunion raction of mammalian DNA topoisomerase II. J Biol Chem 1984; 259: 13560–13566
   PubMedGoogle Scholar
• Minocha A, Long B H. Inhibition of the DNA catenation activity of type II topoisomerase by VP16–213 and VM-26. Biochem Biophys Res Commun 1984; 122: 165–170
   PubMed Web of Science ®Google Scholar
• Ratain M J, Kaminer L S, Bitran J D, et al. Acute non-lymphocytic leukemia following etoposide and cisplatin combination chemotherapy for advance non-small-cell carcinoma of the lung. Blood 1987; 70: 1412–1418
   PubMed Web of Science ®Google Scholar
• Drewinko B, Barlogie B. Survival and cycle-progression delay of human lymphoma cells in vitro exposed to VP-16–213. Cancer Treat Rep 1978; 60: 1295–1306
   Google Scholar
• Venditti J M. Treatment schedule dependency of experimentally active antileukemic (L1210) drugs. Cancer Chemother Rep 1971; 2: 35–59
   Google Scholar
• Vietti T J, Valeriote F A, Kalish R, et al. Kinetics of cytotoxicity of VM-26 and VP-16–213 on L1210 leukemia and hematopoietic stem cells. Cancer Treat Rep 1978; 62: 1313–1320
   PubMedGoogle Scholar
• Slevin M L, Clark P I, Joel S P, et al. A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. J Clin Oncol 1989; 7: 1333–1340
   PubMed Web of Science ®Google Scholar
• Chan K K, Chleboski R T, Myron-Tonn H S, et al. Clinical pharmacokinetics of adriamycin in hepatoma patients with cirrhosis. Cancer Res 1980; 40: 1263–1269
   PubMed Web of Science ®Google Scholar
• Legha S S, Benjamin R S, Mackay B, et al. Adriamycin therapy by continuous intravenous infusion in patients with metastatic breast cancer. Cancer 1982; 49: 1762–1766
   PubMed Web of Science ®Google Scholar
• Hortobagyi G N, Frye D, Buzdar A U, et al. Decreased cardiac toxicity of doxorubicin administration by continuous intravenous infusion in combination chemotherapy for metastatic breast carcinoma. Cancer 1989; 63: 37–45
   PubMed Web of Science ®Google Scholar
• Legha S S, Benjamin R S, Mackay B, et al. Reduction of doxorubicin cardiotoxicity by prolonged continuous intravenous infusion. Ann Intern Med 1982; 96: 133–139
   PubMed Web of Science ®Google Scholar
• Plunkett W, Liliemark J O, Estey E, et al. Saturatic of ara-CTP accumulation during high-dose ara-C therapy: Pharmacologic rationale for interniediale-dose Ara-C. Semin Oncol 14(2) Suppl 1989; 1: 159–166
   Google Scholar
• Chabner B A. Cytosine arabinoside. Pharmacologic Principles of Cancer Treatment, B A Chabner. WB Saunders, Philadelphia 1982; 387–401
   Google Scholar
• Drewinko B, Ho D HW, Barranco S C. The effects of arabinosylcy-tosine on cultured human lymphoma cells. Cancer Res 1972; 42: 1587–1594
   Google Scholar
• Velasquez W S, McLaughlin P, Tucker S, et al. ESHAP—An effective chemotherapy regimen in refractory and relapsing lymphoma: A 4-year follow-up study. J Clin Oncol 1994; 12: 1169–1176
   PubMed Web of Science ®Google Scholar
• Valasquez W, Cabanillas F, Salvador P, et al. Effective salvage therapy for lymphoma with cisplatin in combination with high-dose Ara-C and dexamethasone (DHAP). Blood 1988; 71: 117–122
   PubMed Web of Science ®Google Scholar
• Chabner B A, Young R C. Threshold methotrexate concentration fain vivo inhibition of DNA synthesis in normal and tumorous target tissues. J Clin Invest 1973; 52: 1804–1811
   PubMed Web of Science ®Google Scholar
• Eichholtz H, Trott K R. Effect of methotrexate concentration and exposure time on mammalian cell survival in vitro. Br J Cancer 1985; 41: 227–284
   Google Scholar
• Taylor S G, McGuire W P, Hauck W W, et al. A randomized comparison of high-dose infusion methotrexate versus standard-dose weekly therapy in head and neck squamous cancer. J Clin Oncol 1984; 2: 1006–1011
   PubMed Web of Science ®Google Scholar
• Vogler W, Jacobs J, Moffitt S, et al. Methotrexate therapy with or without citrovorum factor in carcinoma of the head and neck, breast and colon. Cancer Clin Trials 1979; 2: 227–236
   Google Scholar
• Druckrey H. Theoretical use of chemotherapy in the treatment of carcinoma. J Kansar (Ankara) 1970; 1: 130–149
   Google Scholar
• Goldin A, Venditti J M, Kline I. Preclinical investigations with ifosphamide in relation to cyclophosphamide. Proceedings of the International Holoxan Symposium, H Burkert, H C Voight. Dusseldorf, Germany 1977; 19–28
   Google Scholar
• Hollisler D, Silver R T, Gordon B, et al. Continuous infusion vincristine and bleomycin with high dose methotrexate for resistant non-Hodgkin's lymphoma. Cancer 1982; 50: 1690–1694
   PubMed Web of Science ®Google Scholar
• Ginsberg S J, Cooke S T, Bloomfield C O, et al. Cyclophosphamide, doxorubicin, vincristine, and low-dose continuous infusion bleomycin in non-Hodgkin's lymphoma: Cancer and Leukemia Group B Study #7804. Cancer 1982; 49: 1346–1352
   PubMed Web of Science ®Google Scholar
• Boyd D B, Coleman M, Papish S W, et al. COPBLAM IIP: Infusional combination chemotherapy for diffuse large cell lymphoma. J Clin Oncol 1988; 6: 425–433
   PubMed Web of Science ®Google Scholar
• Coleman M, Armitage J O, Gaynor M, et al. The COP-BLAM programs: Evolving chemotherapy concepts in large cell lymphoma. Semin Hematol 1988; 25(2)22–33, (Suppl 2)
   Google Scholar
• Yi P I, Coleman M, Saltz L, et al. Chemotherapy for large cell lymphoma. Semin Oncol 1990; 17: 60–73
   PubMed Web of Science ®Google Scholar
• Armitage J O, Fyfe M A, Lewis J. Long-term remission durability and functional status of patients treated for diffuse histiocytic lymphomas with the CHOP regimen. J Clin Oncol 1984; 2: 898–902
   PubMed Web of Science ®Google Scholar
• Klimo P, Connors J M. MACOP-B Chemotherapy for the treatment of diffuse large cell lymphoma. Ann Intem Med 1985; 102: 596–602
   PubMed Web of Science ®Google Scholar
• Longo D L, Devita V T, Duffey P L, et al. Superiority of ProMACE-CytaBOM over ProMACE-MOPP in the treatment of advanced diffuse aggressive lymphoma: Results of a prospective randomized trial. J Clin Oncol 1991; 9: 25–38
   PubMed Web of Science ®Google Scholar
• Fisher R I, Gaynor E R, Dahlberg S, et al. Comparison of a standard regimen (CHOP) with three intensive chemotherapy regimens for advanced non-Hodgkin's lymphoma. N Engl J Med 1993; 328: 1002–1006
   PubMed Web of Science ®Google Scholar
• Wilson W H, Bryant G, Bates S, et al. EPOCH chemotherapy toxicity and efficacy in relapsed and refractory non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1573–1582
   PubMed Web of Science ®Google Scholar
• Carrion J R, Arroyo G, Salinas P. Infusional chemotherapy (EPOCH) in patients with refractory or relapsed lymphoma. Am J Clin Oncol 1995; 18: 44–46
   PubMed Web of Science ®Google Scholar
• Alvarez M, Wilson W H, Setser A, et al. Phase II study of EPOCH chemotherapy in previously untreated intermediate-grade (IG) non-Hodgkin's lymphomas (NHL). Blood 1995; 86(10), (Suppl 1) (abstract 1083)
   PubMed Web of Science ®Google Scholar
• The international Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 392: 987–994
   Google Scholar
• Sparano J A, Wiemik P H, Strack M, et al. Infusional cyclophosphamide, doxorubicin and etoposide in HIV-related non-Hodgkin's lymphoma: A follow-up report of a highly active regimen. Leukemia Lymphoma 1994; 14: 263–271
   PubMed Web of Science ®Google Scholar
• Sparano J A, Wiernik P H, Leaf A, et al. Infusional cyclophosphamide, doxorubicin, and etoposide in relapsed and resistant non-Hodgkin's lymphoma: Evidence for a schedule-dependent effect favoring infusional administration of chemotherapy. J Clin Oncol 1993; 11: 1071–1079
   PubMed Web of Science ®Google Scholar